Phase III LINC 3 Study Demonstrates That ISTURISA® (osilodrostat) Improves Physical Features Associated With Hypercortisolism in Patients With Cushing's Disease

Phase III LINC 3 Study Demonstrates That ISTURISA® (osilodrostat) Improves Physical Features Associated With Hypercortisolism in Patients With Cushing’s Disease - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

Italy ,Milan ,Lombardia ,United States ,Lebanon ,America ,American ,Mohamed Ladha ,American Association Of Clinical Endocrinology ,Recordati Rare Diseases Inc ,Head Of Clinical Development Medical Affairs ,Recordati Group ,Rare Diseases ,American Association ,Clinical Endocrinology ,Alberto Pedroncelli ,Clinical Development ,Medical Affairs ,Global Endocrinology ,Therapy Improves Physical Features Associated ,Study Findings ,General Manager North ,Recordati Rare Diseases ,Lancet Diabetes ,Rare Disease ,Resume ,Careers ,Hase Iii Linc 3 Study Demonstrates That Isturisa Osilodrostat Improves Physical Features Associated With Hypercortisolism In Patients Cushings Disease ,Iospace ,Advice ,